2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Severe Hemophilia B: new trials by email Literature Review of Severe Hemophilia B trials Research Report on Severe Hemophilia B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B rFIXFc - Severe Hemophilia B | Phase 3 | Completed | Bioverativ Therapeutics Inc. | 120 | 2011-12-08 | 2020-12-19 |
| Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B Factor IX (rFIXFc), rFIX - Severe Hemophilia B | Phase 3 | Completed | Bioverativ Therapeutics Inc. | 123 | 2009-12-01 | 2020-12-19 |
Hemophilia B (2)
Blood Coagulation Disorders (2) · Blood Coagulation Disorders, Inherited (2) · Coagulation Protein Disorders (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Genetic Diseases, X-Linked (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2)
Factor IX (1) · factor IX Fc fusion protein (1)
Bioverativ Therapeutics Inc. (2)
Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · China (2) · France (2) · Germany (2) · Hong Kong (2) · India (2) · Italy (2) · Japan (2) · Poland (2) · South Africa (2) · Sweden (2) · United Kingdom (2)
PMID 36848635, PMID 24304002, PMID 30656283, PMID 37283819
2009 (1)